Purpose: The objective of this pilot study was to evaluate the efficacy and safety of 5% imiquimod cream in the treatment of periocular basal cell carcinoma (BCC) through the analysis of a case series. Methods: Eight subjects with primary nodular BCC of the eyelid were recruited. Treatment lasted 10 to 16 weeks. The average follow-up time was 11.7 months. Results: Of a total of 10 lesions, 80% resolved clinically and histologically and have remained asymptomatic since. Conclusion: Imiquimod cream 5% was shown to be an attractive alternative to surgical treatment of periocular BCC. Future studies with larger samples and longer follow-up periods are expected to provide more accurate information on the efficacy and safety of the drug
Os autores descrevem um paciente com carcinoma basocelular nodular em canto medial tratado com imiqu...
The aim. investigation of the possibilities of dermatoscopy as a method for evaluating the effective...
Copyright 2007 Adis Data Information BVBasal cell carcinoma (BCC) is the most common non-melanoma sk...
Purpose: The objective of this pilot study was to evaluate the efficacy and safety of 5% imiquimod c...
BACKGROUND: Topical treatment with 5% imiquimod cream has been demonstrated to be effective in patie...
OBJETIVO: Avaliar a eficácia e segurança da imunoterapia tópica com imiquimode creme 5% no tratament...
BACKGROUND Imiquimod 5% topical cream is approved for treatment of superficial basal cell carcinoma ...
Objectives: This study was designed to compare the safety and efficacy of two cycled dosing regimens...
Background: Basal cell carcinoma (BCC) and squamous intra-epidermal carcinoma (IEC) are the most com...
Superficial basal cell carcinoma comprise up to 25% of all histological sub-types. They are more lik...
Background: Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatm...
Published Online First 10 August 2010Aim: To describe the ophthalmic side-effects of topical imiquim...
Basal cell carcinoma (BCC) is the most common malignant skin tumor, amongst which the nodular, nodul...
Background: Patients with basal cell carcinoma (BCC) have an increased risk of subsequent BCCs. It...
SummaryBackgroundBasal-cell carcinoma is the most common form of skin cancer and its incidence is in...
Os autores descrevem um paciente com carcinoma basocelular nodular em canto medial tratado com imiqu...
The aim. investigation of the possibilities of dermatoscopy as a method for evaluating the effective...
Copyright 2007 Adis Data Information BVBasal cell carcinoma (BCC) is the most common non-melanoma sk...
Purpose: The objective of this pilot study was to evaluate the efficacy and safety of 5% imiquimod c...
BACKGROUND: Topical treatment with 5% imiquimod cream has been demonstrated to be effective in patie...
OBJETIVO: Avaliar a eficácia e segurança da imunoterapia tópica com imiquimode creme 5% no tratament...
BACKGROUND Imiquimod 5% topical cream is approved for treatment of superficial basal cell carcinoma ...
Objectives: This study was designed to compare the safety and efficacy of two cycled dosing regimens...
Background: Basal cell carcinoma (BCC) and squamous intra-epidermal carcinoma (IEC) are the most com...
Superficial basal cell carcinoma comprise up to 25% of all histological sub-types. They are more lik...
Background: Although the effectiveness of daily dosing regimens of 5% imiquimod cream for the treatm...
Published Online First 10 August 2010Aim: To describe the ophthalmic side-effects of topical imiquim...
Basal cell carcinoma (BCC) is the most common malignant skin tumor, amongst which the nodular, nodul...
Background: Patients with basal cell carcinoma (BCC) have an increased risk of subsequent BCCs. It...
SummaryBackgroundBasal-cell carcinoma is the most common form of skin cancer and its incidence is in...
Os autores descrevem um paciente com carcinoma basocelular nodular em canto medial tratado com imiqu...
The aim. investigation of the possibilities of dermatoscopy as a method for evaluating the effective...
Copyright 2007 Adis Data Information BVBasal cell carcinoma (BCC) is the most common non-melanoma sk...